Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2015

01-06-2015 | Editorial

Growth hormone deficiency in patients with obesity

Author: Roberto Salvatori

Published in: Endocrine | Issue 2/2015

Login to get access

Excerpt

It is well known that the growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis-in addition to regulating somatic growth exerts important metabolic actions and regulates body composition [1]. GH (like insulin) is essential in adapting the utilization of calories to the amount of ingested food, promoting anabolism when caloric supply exceeds demands, and catabolism in the opposite situation. While insulin is the main metabolic hormone in the fed state, GH assumes a key role as stimulator of lipolysis during prolonged fasting, when it causes preferential oxidation of lipids and protein synthesis [2]. The increase in GH secretion that occurs with fasting may have represented an evolutionary advantage in times of food scarcity. However, GH and IGF-I have opposite effects on glucose homeostasis, with the former reducing insulin sensitivity (mainly acting in the liver) and the latter increasing it in the muscle. …
Literature
1.
A. Bartke, L.Y. Sun, V. Longo, Somatotropic signaling: trade-offs between growth, reproductive development, and longevity. Physiol. Rev. 2013(93), 571–598 (2013)CrossRef
2.
A.A. Sakharova, J.F. Horowitz, S. Surya, N. Goldenberg, M.P. Harber, K. Symons, A. Barkan, Role of growth hormone in regulating lipolysis, proteolysis, and hepatic glucose production during fasting. J. Clin. Endocrinol. Metab. 93, 2755–2759 (2008)CrossRefPubMedCentralPubMed
3.
S. Savastano, C. Di Somma, L. Barrea, A. Colao, The complex relationship between obesity and the somatropic axis: the long and winding road. Growth Horm. IGF Res. 24, 221–226 (2014)CrossRefPubMed
4.
M.E. Molitch, D.R. Clemmons, S. Malozowski, G.R. Merriam, M.L. Vance, Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1587–1609 (2011)CrossRefPubMed
5.
A. Agha, J.P. Monson, Modulation of glucocorticoid metabolism by the growth hormone - IGF-1 axis. Clin. Endocrinol. (Oxf.) 66, 459–465 (2007)
6.
J.D. Veldhuis, A. Iranmanesh, K.K. Ho, M.J. Waters, M.L. Johnson, G. Lizarralde, Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J. Clin. Endocrinol. Metab. 72, 51–59 (1991)CrossRefPubMed
7.
C. Lubrano, M. Tenuta, D. Costantini, P. Specchia, G. Barbaro, S. Basciani, S. Mariani, A. Pontecorvi, A. Lenzi, L. Gnessi, Severe growth hormone deficiency end empty sella in obesity: a cross sectional study. Endocrine (2015). doi:10.​1007/​s12020-015-0530-0
8.
M. Gasperi, G. Aimaretti, E. Cecconi, A. Colao, C. Di Somma, S. Cannavò, C. Baffoni, M. Cosottini, L. Curtò, F. Trimarchi, G. Lombardi, L. Grasso, E. Ghigo, E. Martino, Impairment of GH secretion in adults with primary empty sella. J. Endocrinol. Invest. 25, 329–333 (2002)CrossRefPubMed
9.
C.L. Deal, M. Tony, C. Höybye, D.B. Allen, M. Tauber, J.S. Christiansen, Growth Hormone in Prader-Willi Syndrome Clinical Care Guidelines Workshop Participants. Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 98, E1072–E1087 (2013)CrossRefPubMedCentralPubMed
10.
D.E. Berryman, C.A. Glad, E.O. List, G. Johannsson, The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat. Rev. Endocrinol. 9, 346–356 (2013)CrossRefPubMed
11.
E. Gomes-Santos, R. Salvatori, T.O. Ferrão, C.R.P. Oliveira, R.D.C.A. Diniz, J.A.M. Santana, F.A. Pereira, R.A.A. Barbosa, A.H.O. Souza, E.V. Melo, C.C. Epitácio-Pereira, A. Alves, I.A.S. Oliveira, J.A. Machado, F.J. Santana-Júnior, J.A.S. Barreto-Filho, M.H. Aguiar-Oliveira, Increased visceral adiposity and cortisol to cortisone ratio in adults with congenital lifetime isolated GH deficiency. J. Clin. Endocrinol. Metab. 99, 3285–3289 (2014)CrossRefPubMed
12.
G. Corneli, C. Di Somma, R. Baldelli, S. Rovere, V. Gasco, C.G. Croce, S. Grottoli, M. Maccario, A. Colao, G. Lombardi, E. Ghigo, F. Camanni, G. Aimaretti, The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur. J. Endocrinol. 153, 257–264 (2005)CrossRefPubMed
13.
L.E. Dichtel, K.C. Yuen, M.A. Bredella, A.V. Gerweck, B.M. Russell, A.D. Riccio, M.H. Gurel, P.M. Sluss, B.M. Biller, K.K. Miller, Overweight/Obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency. J. Clin. Endocrinol. Metab. 99, 4712–4719 (2014)CrossRefPubMed
14.
M.H. Rasmussen, A. Hvidberg, A. Juul, K.M. Main, A. Gotfredsen, N.E. Skakkebaek, J. Hilsted, N.E. Skakkebae, Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J. Clin. Endocrinol. Metab. 80, 1407–1415 (1995)PubMed
15.
H. Makimura, T. Stanley, D. Mun, S.M. You, S. Grinspoon, The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men. J. Clin. Endocrinol. Metab. 93, 4254–4260 (2008)CrossRefPubMedCentralPubMed
16.
D.R. Clemmons, M. Molitch, A.R. Hoffman, A. Klibanski, C.J. Strasburger, D.L. Kleinberg, K. Ho, S.M. Webb, M.D. Bronstein, R. Bouillon, A. Ben-Shlomo, A.H. Hamrahian, P. Chanson, A.L. Barkan, G.R. Merriam, M.R. Blackman, R. Salvatori, Growth hormone should be used only for approved indications. J. Clin. Endocrinol. Metab. 99, 409–411 (2014)CrossRefPubMed
Metadata
Title
Growth hormone deficiency in patients with obesity
Author
Roberto Salvatori
Publication date
01-06-2015
Publisher
Springer US
Published in
Endocrine / Issue 2/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0571-4

Other articles of this Issue 2/2015

Endocrine 2/2015 Go to the issue

Endocrine Imaging

Positive 68Ga-DOTATOC-PET/CT after cortisol level control during ketoconazole treatment in a patient with liver metastases from a pancreatic neuroendocrine tumor and ectopic Cushing syndrome

Research Letter

Protective effects of coenzyme Q10 and aspartic acid on oxidative stress and DNA damage in subjects affected by idiopathic asthenozoospermia

Research Letter

Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease

Original Article

Activating autoantibodies to the β1/2-adrenergic and M2 muscarinic receptors associate with atrial tachyarrhythmias in patients with hyperthyroidism

Research Letter

Hypogonadotropic hypogonadism in a female patient previously diagnosed as having waardenburg syndrome due to a sox10 mutation

Review

Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits